• Something wrong with this record ?

Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists

P. Baji, L. Gulácsi, PA. Golovics, BD. Lovász, M. Péntek, V. Brodszky, F. Rencz, PL. Lakatos,

. 2016 ; 10 (-) : 85-90. [pub] 20161005

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18034053

BACKGROUND: In middle-income countries, access to biological therapy is limited in ulcerative colitis in terms of the number of patients and the length of therapy. Because of their cost advantages, biosimilars have the potential to improve access to therapy, but physicians have concerns toward their use because of the lack of evidence from randomized clinical trials. OBJECTIVES: To explore the preferences of gastroenterologists for biosimilar drugs in ulcerative colitis as well as to compare our results with results of previous studies on gastroenterologists' preferences toward biosimilars. METHODS: A discrete choice experiment was carried out involving 51 Hungarian gastroenterologists treating patients with inflammatory bowel disease in May 2014 with the following attributes: type of treatment (biosimilar/originator), severity of disease, availability of continuous medicine supply, and the stopping rule (whether the treatment is covered after 12 months). A conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: According to the results, the stopping rule was the most important attribute. The type of treatment mattered only for patients already on biologicals. The probabilities of choosing the biosimilar option with all the benefits offered in the discrete choice experiment over the originator option under the present reimbursement conditions are 85% for new patients and 63% for patients already treated. CONCLUSIONS: Most gastroenterologists have concerns about using biosimilars. They, however, are willing to consider the use of biosimilars if they could reallocate the potential savings to provide their patients better access to biological treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18034053
003      
CZ-PrNML
005      
20181203090639.0
007      
ta
008      
181008s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vhri.2016.07.004 $2 doi
035    __
$a (PubMed)27881284
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Baji, Petra $u Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary; CERGE-EI, Nové Město, The Czech Republic.
245    10
$a Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists / $c P. Baji, L. Gulácsi, PA. Golovics, BD. Lovász, M. Péntek, V. Brodszky, F. Rencz, PL. Lakatos,
520    9_
$a BACKGROUND: In middle-income countries, access to biological therapy is limited in ulcerative colitis in terms of the number of patients and the length of therapy. Because of their cost advantages, biosimilars have the potential to improve access to therapy, but physicians have concerns toward their use because of the lack of evidence from randomized clinical trials. OBJECTIVES: To explore the preferences of gastroenterologists for biosimilar drugs in ulcerative colitis as well as to compare our results with results of previous studies on gastroenterologists' preferences toward biosimilars. METHODS: A discrete choice experiment was carried out involving 51 Hungarian gastroenterologists treating patients with inflammatory bowel disease in May 2014 with the following attributes: type of treatment (biosimilar/originator), severity of disease, availability of continuous medicine supply, and the stopping rule (whether the treatment is covered after 12 months). A conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: According to the results, the stopping rule was the most important attribute. The type of treatment mattered only for patients already on biologicals. The probabilities of choosing the biosimilar option with all the benefits offered in the discrete choice experiment over the originator option under the present reimbursement conditions are 85% for new patients and 63% for patients already treated. CONCLUSIONS: Most gastroenterologists have concerns about using biosimilars. They, however, are willing to consider the use of biosimilars if they could reallocate the potential savings to provide their patients better access to biological treatment.
650    _2
$a monoklonální protilátky $7 D000911
650    _2
$a biosimilární léčivé přípravky $x terapeutické užití $7 D059451
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a Crohnova nemoc $7 D003424
650    12
$a gastroenterologové $7 D000072102
650    _2
$a gastrointestinální látky $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a Maďarsko $7 D006814
650    _2
$a idiopatické střevní záněty $7 D015212
650    _2
$a infliximab $7 D000069285
650    12
$a lékařská praxe - způsoby provádění $7 D010818
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gulácsi, László $u Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary. Electronic address: laszlo.gulacsi@uni-corvinus.hu.
700    1_
$a Golovics, Petra A $u First Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Lovász, Barbara D $u First Department of Medicine, Semmelweis University, Budapest, Hungary.
700    1_
$a Péntek, Márta $u Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary; Department of Rheumatology, Flór Ferenc County Hospital, Kistarcsa, Hungary.
700    1_
$a Brodszky, Valentin $u Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary.
700    1_
$a Rencz, Fanni $u Department of Health Economics, Corvinus University of Budapest, Budapest, Hungary; Semmelweis University Doctoral School of Clinical Medicine, Budapest, Hungary.
700    1_
$a Lakatos, Péter L $u First Department of Medicine, Semmelweis University, Budapest, Hungary.
773    0_
$w MED00196873 $t Value in health regional issues $x 2212-1102 $g Roč. 10, č. - (2016), s. 85-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27881284 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181203090751 $b ABA008
999    __
$a ok $b bmc $g 1341025 $s 1031047
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c - $d 85-90 $e 20161005 $i 2212-1102 $m Value in health regional issues $n Value Health Reg Issues $x MED00196873
LZP    __
$a Pubmed-20181008
Back

Find record

Citation metrics

Archiving options